✦ LIBER ✦

Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer

✍ Scribed by H. Sasaki; H. Yukiue; K. Mizuno; A. Sekimura; A. Konishi; M. Yano; M. Kaji; M. Kiriyama; I. Fukai; Y. Yamakawa; Y. Fujii

Publisher: Springer
Year: 2003
Tongue: English
Weight: 186 KB
Volume: 8
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s101470300014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum carcinoembryonic antigen level is

Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas

✍ Fumihiro Shoji; Ichiro Yoshino; Tokujiro Yano; Takuro Kometani; Taro Ohba; Hiden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## BACKGROUND. The presence of epidermal growth factor receptor (EGFR) gene mutations is a good indicator of the clinical efficacy of gefitinib in patients with nonsmall cell lung cancer. It was recently reported that the serum carcinoembryonic antigen (CEA) level could be a predictive

Serum vascular endothelial growth factor

Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma : A possible diagnostic tool for lymph node metastasis

✍ Masaya Tamura; Yasuhiko Ohta 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

## Abstract ## BACKGROUND The authors measured circulating vascular endothelial growth factor‐C (VEGF‐C) and vascular endothelial growth factor (VEGF) levels in patients with primary nonsmall cell lung carcinoma and assessed its usefulness as a diagnostic tool for determining lymph node metastasis

Epidermal growth factor receptor serum (

Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?

✍ M. G. Zampino; E. Magni; L. Santoro; L. Zorzino; P. Dell’Orto; A. Sonzogni; N. F 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 397 KB

Tissue microarray-based studies of patie

Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

✍ Idris Tolgay Ocal; Marisa Dolled-Filhart; Thomas G. D'Aquila; Robert L. Camp; Da 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 542 KB

## Abstract ## BACKGROUND It has been shown that receptor tyrosine kinases (RTKs) predict outcome in patients with breast carcinoma. Although RTKs are a large family, HER‐2, epidermal growth factor receptor (EGFR), Met (hepatocyte growth factor receptor), and others all have shown the ability to p

High pre-treatment serum level of vascul

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

✍ Petri Salven; Tarja Ruotsalainen; Karin Mattson; Heikki Joensuu 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 68 KB 👁 2 views

Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and vascular permeability. Increased serum VEGF concentrations (S-VEGF) have been found in patients with various types of human cancer, including cancer of the lung. However, the clinical and prognostic significance

Epidermal-growth-factor receptor correla

Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus

✍ Doris Pfeiffer; Rainer Kimmig; Jörg Herrmann; Maximilian Ruge; Annette Fisseler- 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 330 KB 👁 3 views

The role of the epidermal-growth-factor receptor (EGFR) in cervical cancer is controversial, due to technical difficulties in localizing or in quantifying EGFR by homogenate assays or immunohistochemistry. Our autoradiographic approach, in combination with morphometry, allowed cell-type-specific qua